Convection-enhanced delivery of a transforming growth factor-beta2 inhibitor trabedersen for recurrent high-grade gliomas: efficacy real or imagined?, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).

Authors	Marc C Chamberlain
Journal	Neuro-oncology (Neuro Oncol) Vol. 13 Issue 5 Pg. 558-9; author reply 561-2 (May 2011) ISSN: 1523-5866 [Electronic] England
PMID	21558078 (Publication Type: Letter, Comment)
Chemical References	Antineoplastic Agents Oligodeoxyribonucleotides Thionucleotides Transforming Growth Factor beta2 Trabedersen
Topics	Antineoplastic Agents (administration & dosage) Brain Neoplasms (drug therapy, metabolism) Clinical Trials, Phase II as Topic Drug Delivery Systems Glioma (drug therapy, metabolism) Humans Neoplasm Recurrence, Local (drug therapy, pathology) Oligodeoxyribonucleotides (administration & dosage) Randomized Controlled Trials as Topic Survival Rate Thionucleotides (administration & dosage) Transforming Growth Factor beta2 (antagonists & inhibitors, metabolism) Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!